8 results about "Blood Coagulation Factor X" patented technology

There has been demand for a pharmaceutical composition containing blood coagulation factor X in which the amount of FXa is suppressed. Provided is a pharmaceutical composition containing blood coagulation factor X, the pharmaceutical composition furthermore containing antithrombin III.

A pharmaceutical composition comprising blood coagulation factor X for use in the treatment of a subject having hemophilia type A is provided. The present invention relates to a pharmaceutical composition, which is a pharmaceutical composition comprising blood coagulation factor X for use in the treatment of a subject having hemophilia type A wherein the blood coagulation factor X is used in combination with a bispecific antibody that binds to activated blood coagulation factor IX and blood coagulation factor X.

The invention relates to the technical field of biomarkers, in particular to a biomarker influencing the intramuscular fat content of chicken and application of the biomarker. The invention relates to a biomarker for influencing the intramuscular fat content of chicken. The biomarker is a blood coagulation factor X. Experiments find that the blood coagulation factor X has significant difference in high intramuscular fat chicken and low intramuscular fat chicken, and can be used for identifying the intramuscular fat content of Gushi chicken and breeding the Gushi chicken with high intramuscular fat. The invention further provides application and a screening method of the serum biochemical marker, and a new thought is provided for local chicken breeding.

The application belongs to the technical field of mass spectrometry, and particularly relates to a mass spectrometry detection method and application of intracellular blood coagulation factor X, which comprises the following steps: specifically enriching ectopic synthesis of blood coagulation factor X in tumor cells to obtain a protein sample; performing protein sample fixation and treatment on the protein sample by using SDS-PAGE gel electrophoresis, placing the gel in an ice box after scanning the gel by using a gel imaging system, and storing the gel; performing in-gel enzymatic digestion on the blood coagulation factor X in the gel to obtain a peptide segment solution; detecting the endogenous synthesis of blood coagulation factor X in tumor cells by using mass spectrometry technology, and obtaining mass spectrometry data. The application firstly adopts the mass spectrometry technology to detect the blood coagulation factor X synthesized by tumor cells outside normal liver cells, specifically enriches the ectopic synthesis of blood coagulation factor X in glioma cells by using the protein immunoprecipitation technology, performs SDS-PAGE gel electrophoresis, performs in-gel enzymatic digestion, and detects the endogenous synthesis of blood coagulation factor X in tumor cells by using the mass spectrometry technology.

Provided is a pharmaceutical composition for treating a subject receiving treatment with a direct oral anticoagulant targeting activated blood coagulation factor X. This pharmaceutical composition contains activated blood coagulation factor VII and blood coagulation factor X and is for treating a subject receiving treatment with a direct oral anticoagulant targeting activated blood coagulation factor X.

The application discloses use of a low molecular weight dextran sulfate derivative in preparation of an anticoagulant drug, the low molecular weight dextran sulfate derivative is shown as formula (I), wherein a main connection mode is an alpha-(1, 6)-glycosidic bond main chain, relates to a weight average molecular weight (M w )≤40 kDa, and each glucose unit has at least 1.0-2.0 sulfate groups on average, wherein the low molecular weight dextran sulfate derivative has a high selective inhibitory activity on a blood coagulation factor X enzyme, so as to inhibit an endogenous blood coagulation pathway; can effectively inhibit thrombosis in vivo and in vitro, and has potential as a novel endogenous anticoagulant.

The invention relates to the technical field of biomarkers, in particular to application of a blood coagulation factor X as a biomarker influencing the abdominal fat percentage of chicken. The invention discloses a biomarker influencing the abdominal fat percentage of chicken. The biomarker is a blood coagulation factor X. Experimental data provided by the invention show that F10 shows a significant difference (Plt; P1t) between groups with high abdominal fat percentage (AFP > = 18%) and groups with low abdominal fat percentage (AFP < = 12%); 0.05), and the biochemical marker combination can be used as a specific molecular marker for the abdominal fat mass of the Gushi chicken. On the basis, a molecular marker assisted breeding system containing serum F10 concentration detection, TG level evaluation and phenotype data association analysis is established, and an innovative technical path is provided for high-quality breeding of Henan local chicken germplasm resources.

The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and / or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII can be prevented and / or treated more effectively.